Not all varieties of botulinum toxin seem to be equally effective in reducing crow’s feet wrinkles, according to a report published Online First today by Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.

Botulinum toxin, a protein long considered harmful, is now known as a neuromodulator (a chemical that affects nerve impulses) that has cosmetic and medical uses, according to background information in the article. In 1989, botulinum toxin type A was approved in the United States for two muscular conditions that affect the appearance of the eyes. In 2002, one type—onabotulinumtoxinA—was approved for the treatment of wrinkles between the eyebrows; a second type, abobotulinumtoxinA, received approval for the same indication in 2009. The authors sought to compare both types of the protein, head to head. “Such an assessment could characterize and contrast their efficacy in clinical performance in the treatment of hyperfunctional lines and muscular relaxation,” the authors write.

Kartik D. Nettar, M.D., from The Maas Clinic, San Francisco, and the University of California, San Francisco, and colleagues conducted a randomized, double-blind split-face study, using one agent on the right side and the other agent on the left side. “By using a split-face (internally controlled) paradigm, this would provide direct comparison of each product in the same patient,” they explain. Ninety patients received injections of onabotulinumtoxinA and of abobotulinumtoxinA on either side of their faces; the lateral orbital rhytids, or “crow’s feet” wrinkles, were the site treated. Investigators assessed the site’s appearance using a five-point scale, and patients were also surveyed for their opinions.

According to the researchers, the difference between the two agents was significant when participants contracted the muscles as much as possible, with abobotulinumtoxinA producing a greater effect. This difference persisted in both investigators’ and patients’ assessments. Approximately two-thirds of participants said they favored the side of their faces that was treated with abobotulinumtoxinA.

The authors remark that the study’s results, while favorable to abobotulinumtoxinA, are limited in their scope. No statistical significance between the two agents was seen when the muscles were at rest. The researchers call for further comparative studies in other facial muscles, as well as of why one agent would perform better than the other. “Ongoing studies will determine whether the demonstrated patient preference and early advantage in clinical outcomes is persistent,” they write, “as both the efficacy in line effacement and duration of effect are both important factors in patient and physician decision-making as it related to the use of neuromodulators.”

###

(Arch Facial Plast Surg. 2011;doi:10.1001/archfacial/2011.37. Available pre-embargo to the media at http://www.jamamedia.org.)

Editor’s Note: Funding for this study was solicited from both Medicis Aesthetics Inc and Allergan Inc. Medicis Aesthetics Inc funded this study. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To contact corresponding author Corey S. Maas, M.D., call Elizabeth Fernandez at 415-502-6397 or e-mail .(JavaScript must be enabled to view this email address).

###

Contact: Elizabeth Fernandez
.(JavaScript must be enabled to view this email address)
415-502-6397
JAMA and Archives Journals